Repligen (Repligen) Total Liabilities : $853.2 Mil (As of Dec. 2023)

View and export this data going back to 1986. Start your Free Trial

What is Repligen Total Liabilities?

Repligen's Total Liabilities for the quarter that ended in Dec. 2023 was $853.2 Mil.

Repligen's quarterly Total Liabilities declined from Jun. 2023 ($578.08 Mil) to Sep. 2023 ($525.57 Mil) but then increased from Sep. 2023 ($525.57 Mil) to Dec. 2023 ($853.21 Mil).

Repligen's annual Total Liabilities increased from Dec. 2021 ($608.29 Mil) to Dec. 2022 ($613.96 Mil) and increased from Dec. 2022 ($613.96 Mil) to Dec. 2023 ($853.21 Mil).

Repligen Total Liabilities Historical Data

The historical data trend for Repligen's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Repligen Total Liabilities Chart

Repligen Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Total Liabilities

Get a 7-Day Free Trial

340.35

373.74

608.29

613.96

853.21

Repligen Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Total Liabilities	Get a 7-Day Free Trial															613.96	597.74	578.08	525.57	853.21

Repligen Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Repligen's Total Liabilities for the fiscal year that ended in Dec. 2023 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	158.162	+	(636.721	+	17.859
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	40.466	+	0)
	=	853.2

Total Liabilities	=	Total Assets (A: Dec. 2023 )	-	Total Equity (A: Dec. 2023 )
	=	2824.411	-	1971.203
	=	853.2

Repligen's Total Liabilities for the quarter that ended in Dec. 2023 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	158.162	+	(636.721	+	17.859
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	40.466	+	0)
	=	853.2

Total Liabilities	=	Total Assets (Q: Dec. 2023 )	-	Total Equity (Q: Dec. 2023 )
	=	2824.411	-	1971.203
	=	853.2

Repligen Total Liabilities Related Terms

Thank you for viewing the detailed overview of Repligen's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Repligen (Repligen) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Repligen Corp (NAS:RGEN) » Definitions » Total Liabilities

Comparable Companies

Traded in Other Exchanges

RGN:Germany RGN:Germany

Address

41 Seyon Street, Building 1, Suite 100, Waltham, MA, USA, 02453

Website

https://www.repligen.com

Repligen Corp is a global life sciences company. It develops and commercializes innovative bioprocessing technologies and systems that increase efficiencies and flexibility in the process of manufacturing biological drugs. The company's customers include life science companies, global biopharmaceutical companies, and contract manufacturers worldwide. Repligen markets its products globally through a direct commercial organization in the U.S., Europe, and Asia, as well as through strategic partners in select markets. The majority of the company's revenue is generated in North America.

Executives

Christine Gebski	officer: See Remarks	C/O REPLIGEN CORPORATION, 41 SYON ST. BLDG. 1, SUITE 100, WALTHAM MA 02453
Olivier Loeillot	officer: President and CCO	C/O REPLIGEN CORPORATION, 41 SEYON STREET, BUILDING 1, SUITE 100, WALTHAM MA 02453
Jason K Garland	officer: CFO	10000 WEHRLE DRIVE, CLARENCE NY 14031
Karen A Dawes	director	579 BELLEVUE AVE, NEWPORT RI 02840
Martin D Madaus	director	290 CONCORD ROAD, BILLERICA MA 01821
Jon Snodgres	officer: CFO	REPLIGEN CORPORATION, 41 SEYON STREET, BUILDING #1, SUITE 100, WALTHAM MA 02435
Anthony Hunt	director, officer: Chief Executive Officer	41 SEYON STREET, BUILDING 1, SUITE 100, WALTHAM MA 02452
Ralf Kuriyel	officer: Senior VP, R&D	41 SEYON ST, BLDG 1, STE. 100, WALTHAM MA 02452
James Bylund	officer: SVP, Global Operations & IT	C/O REPLIGEN CORPORATION, 41 SYON ST. BLDG. SUITE 100, WALTHAM MA 02453
Konstantin Konstantinov	director	C/O CODIAK BIOSCIENCES, INC., 500 TECHNOLOGY SQUARE, 9TH FLOOR, CAMBRIDGE MA 02139
Manner Carrie Eglinton	director	C/O QUEST DIAGNOSTICS, 500 PLAZA DRIVE, SECAUCUS NJ 07094
Ryan Thomas F Jr	director
Nicolas Barthelemy	director	1750 BELLA LAGUNA CT, ENCINITAS CA 92024
John Cox	director	C/O BIOVERATIV INC., 225 SECOND AVENUE, WALTHAM MA 02451
Rohin Mhatre	director	C/O REPLIGEN CORP., 41 SEYON STREET, BUILDING 1, SUITE 100, WALTHAM MA 02453